[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account
arrow_back

Go back to trials list

Serial Amnioinfusions As Regenerative Therapy for Pulmonary Hypoplasia in Fetuses with Intrauterine Renal Failure or Severe Renal Anomalies- a Feasibility Study


Description

Congenital lower urinary tract obstruction (LUTO) is a heterogeneous group of congenital anomalies that lead bladder outlet obstruction. If a complete obstruction is present, the perinatal mortality is estimated to be as high as 90% because of severe pulmonary hypoplasia due to the lack of amniotic fluid. Survivors have significant risk of renal impairment (90%) requiring dialysis or renal transplantation if no fetal intervention is performed. Renal agenesis is the congenital absence of one or both kidneys due to complete failure of the kidney to form. As many as 33% of fetuses with bilateral renal agenesis are stillborn, and the rest of them die immediately after birth due to severe pulmonary hypoplasia. The objective of the serial amnioinfusions for fetuses with these conditions will be to reduce the severity of pulmonary hypoplasia (regenerating the lung functionality) and therefore increase the chance that the newborn survives to begin peritoneal dialysis. Although there is initi

Trial Eligibility

Inclusion Criteria: * Pregnant women with singleton uterine pregnancy * Maternal age \> age 18 * Fetus \< 26 weeks gestational age with severe LUTO and intrauterine renal failure * Fetus \< 26 weeks gestational age with bilateral renal agenesis * Fetus with absence of chromosome abnormalities * Fetus with absence of associated anomalies * Mother has negative Hepatitis B, Hepatitis C, and HIV testing * Mother meets psychosocial criteria that allows her to make a conscious decision about her fetus/infant Exclusion Criteria: * Associated fetal anomaly unrelated to LUTO or renal agenesis * Increased risk for preterm labor including short cervical length, history of incompetent cervix with or without cerclage, and previous preterm birth * Placental abnormalities known at time of enrollment * Maternal-fetal Rh isoimmunization, Kell sensitization or neonatal alloimmune thrombocytopenia affecting the current pregnancy * Maternal medical condition that is a contraindication to surgery or anesthesia * Mother has declined invasive testing * Inability to comply with the travel and follow-up requirements of the trial * Participation in another interventional study that influences maternal and fetal morbidity and mortality * Participation in this clinical trial during a previous pregnancy

Study Info

Organization

Mayo Clinic


Primary Outcome

Adverse Events


Outcome Timeframe First amnioinfusion through delivery which may be up to 22 weeks.

NCTID NCT03723564

Phases PHASE1

Primary Purpose TREATMENT

Start Date 2018-10-01

Completion Date 2025-12-31

Enrollment Target 40

Interventions

DRUG Lactated Ringers Solution for Injection

Locations Recruiting

Mayo Clinic

United States, Minnesota, Rochester


Interested in joining this trial?

Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.

newsletter icon

Get the latest thought leadership on your Kidney Disease delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.